Nearly a quarter of patients survived for more than 3 years. Long-term clinical results of BMS dual immunotherapy are positive

On September 13, 2021, Bristol Myers Squibb (Bristol Myers Squibb) announced the three-year follow-up data of the Phase 3 clinical trial CheckMate-743

Nivolumab (Nivolumab, the English trade name is Opdivo) targets PD-1, which can help the body restore the anti-tumor immune response

MPM is a rare but aggressive cancer that forms on the lining of the lungs

The multi-center, open-label CheckMate-743 trial enrolled 605 patients with unresectable MPM who had not been treated before

The results of the trial followed up for at least 3 years (35.

In the dual immune combination therapy group, 23% of patients were still alive at three years, compared to 15% in the chemotherapy control group

The combination therapy group continued to show a reduced risk of death (HR=0.

The safety characteristics of the combination therapy are consistent with the previously reported data, and no new safety signals have been found

In addition, at 3 years of follow-up (approximately 1 year after the patient ended treatment), regardless of the patient's tumor histological type, the dual immunotherapy combination had a longer duration of remission (DOR) than chemotherapy

28% of patients in the combination therapy group remained in remission at three years, compared with 0% in the chemotherapy group

The median DOR of patients in the combination therapy group was 11.

The objective response rate (ORR) of the combined treatment group was comparable to that of the chemotherapy group (39.

Reference materials:

[1] nivolumab Plus ipilimumab Demonstrates Durable Overall Survival at Three Years Compared to Chemotherapy in First-Line Unresectable Malignant Pleural Mesothelioma in Phase 3 CheckMate -743 Trial.

(The original text has been deleted)